Current Clinical Trials

Sneeze, Wheeze and Itch Associates, LLC

Go Back

House Dust Mite Allergy

  • Number
  • Type
  • Age Range
  • Length of Study
  • Compensation*
  • 75.14
  • House Dust Mite Allergy
  • 12 -65 years of age
  • 14-20 months
  • $65 per completed visit

 

*Qualified participants may receive compensation for time and travel, up to the amount listed.

A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis.

The objective of this study is to assess the efficacy and safety of 12 months of treatment with 300 IR of STG320 sublingual tablets compared with placebo in adults and adolescents with HDM-associated allergic rhinitis.

Main Inclusion Criteria:

  • Patients with HDM-associated allergic rhinitis (AR) for at least 1 year
  • Patients sensitized to D. pteronyssinus (D. pte) and/or D. farinae (D. far) defined on skin prick test and HDM-specific serum IgE

Main Exclusion Criteria:

  • A history of rhinitis, rhinoconjunctivitis or asthma to allergens other than HDM, likely to result in rhinitis symptoms during the evaluation periods
  • Partly controlled or uncontrolled asthma
  • Controlled asthma requiring controller treatment(s) consistent with GINA 2014 treatment Steps 3 to 5

For more information, please call 309-452-0995 and ask to speak to a coordinator.